1279 completed, 434 terminated, 378 recruiting, 295 unknown. 2854 Phase 1, 974 Phase 2.
Follow Lymphoma: new trials by email Literature Review of Lymphoma trials Research Report on Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Multi-CAR-T Cells Targeting B Cell Lymphomas 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL) | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 11 | 2027-06-01 | 2026-11-02 |
| Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides or Sézary Syndrome Biospecimen Collection, Computed Tomography, Cosibelimab - Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome | Phase 1 | Not yet recruiting | City of Hope Medical Center | 14 | 2027-05-16 | 2026-11-09 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL) Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Recruiting | Sunil G. Iyer | 45 | 2027-03-31 | 2026-11-13 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2027-03-26 | 2026-10-20 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Zhujiang Hospital | 15 | 2027-02-01 | 2025-03-30 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2027-02-01 | 2026-11-13 |
| Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Not yet recruiting | Istituto Oncologico Veneto IRCCS | 14 | 2027-01-31 | 2026-11-03 |
| Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma | Phase 1 | Not yet recruiting | The Methodist Hospital Research Institute | 21 | 2027-01-15 | 2026-11-12 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-10-30 |
| A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides Duvelisib - Mycosis Fungoides, Cutaneous T-cell Lymphoma | Phase 1 | Not yet recruiting | SecuraBio | 30 | 2027-01-01 | 2026-07-20 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Study Of KITE-753 in R/R B-Cell ALL KITE-753 - B-cell Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 18 | 2026-12-31 | 2026-09-11 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
Showing 20 of 2854. Sign in to see all of them.
Lymphoma, Non-Hodgkin (963) · Lymphoma, Large B-Cell, Diffuse (674) · Lymphoma, Follicular (608) · Leukemia, Lymphocytic, Chronic, B-Cell (544) · Lymphoma, Mantle-Cell (518) · Burkitt Lymphoma (438) · Hodgkin Disease (437) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (432) · Lymphoma, B-Cell (429) · Lymphoma, B-Cell, Marginal Zone (364) · Recurrence (328) · Leukemia (312) · Multiple Myeloma (269) · Leukemia, Myeloid, Acute (234)
Hemic and Lymphatic Diseases (2847) · Neoplasms by Histologic Type (2841) · Immunoproliferative Disorders (2822) · Immune System Diseases (2820) · Lymphatic Diseases (2820) · Lymphoproliferative Disorders (2801) · Neoplasms (2640) · Lymphoma, Non-Hodgkin (1259) · Hematologic Diseases (1106) · Pathological Conditions, Signs and Symptoms (935) · Pathologic Processes (930) · Disease Attributes (857) · Lymphoma, B-Cell (828) · Leukemia, Lymphoid (802)
Rituximab (312) · Cyclophosphamide (305) · fludarabine (165) · Vincristine (112) · fludarabine phosphate (110) · Lenalidomide (108) · Prednisone (102) · Etoposide (101) · Doxorubicin (98) · Bendamustine Hydrochloride (73) · venetoclax (72) · Gemcitabine (71) · Filgrastim (64) · obinutuzumab (63) · pembrolizumab (63)
National Cancer Institute (NCI) (194) · M.D. Anderson Cancer Center (83) · Memorial Sloan Kettering Cancer Center (52) · City of Hope Medical Center (50) · Celgene (37) · Fred Hutchinson Cancer Center (37) · Hoffmann-La Roche (34) · Baylor College of Medicine (30) · Novartis Pharmaceuticals (30) · Chinese PLA General Hospital (26) · AstraZeneca (24) · AbbVie (23) · Gilead Sciences (23) · Mayo Clinic (23) · Janssen Research & Development, LLC (22)
United States (1852) · China (508) · France (205) · United Kingdom (187) · Spain (182) · Australia (160) · Italy (159) · Canada (157) · Germany (134) · South Korea (109) · Japan (96) · Poland (64) · Belgium (60) · Netherlands (55) · Israel (47)
Ajay Gopal (9)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 19238148, PMID 32499241, PMID 32770353, PMID 33883258, PMID 34780125, PMID 35622074, PMID 39319495, PMID 39813680, PMID 28054442, PMID 32596842, PMID 32632956, PMID 32705923, PMID 32823563, PMID 34687939, PMID 34889384, PMID 37486616, PMID 37981564, PMID 40195173, PMID 40802906, PMID 19451441, PMID 19949018, PMID 20028764, PMID 20188202, PMID 21816833, PMID 22002018, PMID 22045986, PMID 22510871, PMID 24055823, PMID 24443277, PMID 24615776, PMID 24615777, PMID 24615778, PMID 24782509, PMID 25317870, PMID 25381051, PMID 26659915, PMID 27118452, PMID 27482888, PMID 28314699, PMID 28925994, PMID 29296805, PMID 30262660, PMID 30518502, PMID 31050355, PMID 31401903, PMID 31527168, PMID 31723767
2023 (37), P30CA033572 (34), 2015 (27), 2016 (25), P30CA015704 (21), 2018 (20), 2017 (19), 2019 (15), 2014 (13), 2025 (13), P30CA015083 (11), U01CA062502 (10), U01CA076576 (10), U01CA097452 (10), P30CA006973 (9)